31137515|t|Virtual Screening Guided Design, Synthesis and Bioactivity Study of Benzisoselenazolones (BISAs) on Inhibition of c-Met and Its Downstream Signalling Pathways.
31137515|a|c-Met is a transmembrane receptor tyrosine kinase and an important therapeutic target for anticancer drugs. In this study, we designed a small library containing 300 BISAs molecules that consisted of carbohydrates, amino acids, isothiourea, tetramethylthiourea, guanidine and heterocyclic groups and screened c-Met targeting compounds using docking and MM/GBSA. Guided by virtual screening, we synthesised a series of novel compounds and their activity on inhibition of the autophosphorylation of c-Met and its downstream signalling pathway proteins were evaluated. We found a panel of benzisoselenazolones (BISAs) obtained by introducing isothiourea, tetramethylthiourea and heterocyclic groups into the C-ring of Ebselen, including 7a, 7b, 8a, 8b and 12c (with IC50 values of less than 20 muM in MET gene amplified lung cancer cell line EBC-1), exhibited more potent antitumour activity than Ebselen by cell growth assay combined with in vitro biochemical assays. In addition, we also tested the antitumour activity of three cancer cell lines without MET gene amplification/activation, including DLD1, MDA-MB-231 and A549. The neuroblastoma SK-N-SH cells with HGF overexpression which activates MET signalling are sensitive to MET inhibitors. The results reveal that our compounds may be nonspecific multitarget kinase inhibitors, just like type-II small molecule inhibitors. Western blot analysis showed that these inhibitors inhibited autophosphorylation of c-MET, and its downstream signalling pathways, such as PI3K/AKT and MARK/ERK. Results suggest that bensoisoselenones can be used as a scaffold for the design of c-Met inhibiting drug leads, and this study opens up new possibilities for future antitumour drug design.
31137515	68	88	Benzisoselenazolones	Chemical	-
31137515	90	95	BISAs	Chemical	-
31137515	114	119	c-Met	Gene	4233
31137515	160	165	c-Met	Gene	4233
31137515	326	331	BISAs	Chemical	-
31137515	360	373	carbohydrates	Chemical	MESH:D002241
31137515	388	399	isothiourea	Chemical	MESH:D013890
31137515	401	420	tetramethylthiourea	Chemical	MESH:C019107
31137515	422	431	guanidine	Chemical	MESH:D019791
31137515	469	474	c-Met	Gene	4233
31137515	657	662	c-Met	Gene	4233
31137515	746	766	benzisoselenazolones	Chemical	-
31137515	768	773	BISAs	Chemical	-
31137515	799	810	isothiourea	Chemical	MESH:D013890
31137515	812	831	tetramethylthiourea	Chemical	MESH:C019107
31137515	875	882	Ebselen	Chemical	MESH:C042986
31137515	894	912	7a, 7b, 8a, 8b and	Chemical	-
31137515	913	916	12c	Chemical	-
31137515	977	988	lung cancer	Disease	MESH:D008175
31137515	999	1004	EBC-1	CellLine	CVCL:E218
31137515	1054	1061	Ebselen	Chemical	MESH:C042986
31137515	1187	1193	cancer	Disease	MESH:D009369
31137515	1258	1262	DLD1	CellLine	CVCL:0248
31137515	1264	1274	MDA-MB-231	CellLine	CVCL:0062
31137515	1279	1283	A549	CellLine	CVCL:0023
31137515	1289	1302	neuroblastoma	Disease	MESH:D009447
31137515	1303	1310	SK-N-SH	CellLine	CVCL:0531
31137515	1322	1325	HGF	Gene	3082
31137515	1357	1360	MET	Gene	79811
31137515	1389	1392	MET	Gene	79811
31137515	1622	1627	c-MET	Gene	4233
31137515	1682	1685	AKT	Gene	207
31137515	1690	1694	MARK	Gene	4139
31137515	1695	1698	ERK	Gene	2048
31137515	1721	1738	bensoisoselenones	Chemical	-
31137515	1783	1788	c-Met	Gene	4233
31137515	Association	MESH:D009447	3082
31137515	Negative_Correlation	MESH:C042986	MESH:D008175
31137515	Positive_Correlation	3082	79811
31137515	Cotreatment	MESH:C019107	MESH:C042986
31137515	Association	MESH:D009447	79811
31137515	Cotreatment	MESH:C042986	MESH:D013890

